CD3ε is a 20 kD transmembrane protein and is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 plays a critical role in TCR signal transduction, T cell a
Learn moreCD28 (Cluster of Differentiation 28) is one of the molecules expressed on T cells that provide co-stimulatory signals, which are required for T cell activation. CD28 is composed of a single Ig V-like extracellular domain, a transmembrane domain and an int
Learn moreInterferon-gamma (IFN-γ) or type II interferon is a dimerized soluble cytokine that is the only member of the type II class of interferons. It is a cytokine critical for innate and adaptive immunity against viral and intracellular bacterial infections and
Learn more
The InVivoPro Anti-Mouse PD-1(CD279) in vivo antibody, Clone 29F.1A12, has emerged as a cornerstone in preclinical immunotherapy research. Developed by BioXCell, this highly specialized monoclonal antibody targets murine PD-1, a key immune checkpoint
Learn more
The InVivoPro Anti-Mouse CD8α in vivo antibody, Clone 2.43 has become a cornerstone in preclinical immunology research, offering researchers a precise and reliable tool to manipulate and study CD8⁺ T cells, the key cytotoxic effectors of the adaptive imm
Learn more
The InVivoPro Anti-Mouse Ly6G in vivo antibody, Clone 1A8 has emerged as a crucial asset in preclinical research, offering a powerful means to study and manipulate neutrophil functions in various disease models. Ly6G, a cell surface antigen highly express
Learn more
99% Customer Satisfaction
Trusted for reliable results, with 20+ top-tier antibodies and 350+ custom success stories.
High Antibody Production
Rapid response and top-quality output ensure your research needs are instantly met.
Your Trusted Research Partner
Expert support from cutting-edge reagent creation to seamless project optimisation.
Solutions Tailored to You
Agile, premium custom services delivered flexibly, right when and where you need them.
InvivoCrown, founded in 2021 in the Cambridge Science Park, UK, as a deep participant in immunology research, takes "Crowning Science" as its core philosophy and focuses on providing global researchers in the fields of immunology and oncology with high-purity, cost-effective, function-oriented in vivo-grade antibody solutions. Our team integrates cutting-edge technologies with pragmatist concepts. Led by a team of immunology experts from the University of Cambridge and with nearly 20 years of experience in antibody drug development, we have created a product matrix with both excellent performance and cost advantages – from classic immune checkpoint targets (such as PD1/PD-L1) to novel tumo
Get inspired
© 2021-2025 InvivoCrown Limited. All rights reserved.